Considering the clinical features and prognosis of these patients, PRR11 is positively correlated with earlier tumor invasion, advanced clinical stage, TNM classification, more lymph node metastasis and higher Ki-67 ratio, which usually are accompanied by shorter overall survival in TSCC, NSCLC, BRCA, GC, HCC, Pancreatic cancer, Ovarian cancer and Osteosarcoma [1,5,7,11,12,13,14,20,21,22,40,54]. This evidence concerns the gene PRR11 and ovarian cancer.